H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

FDA grants EUA for Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay in CLIA high complexity laboratories

Longhorn Vaccines & Diagnostics today announced it has been granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ in CLIA high complexity laboratories. . The Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ is a ready-use assay that requires no mixing prior to use and has been authorized for use on the ABI 7500.

24 Feb 2010

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Diagnostic Hybrids, a Quidel Company has received emergency use authorization from the U.S. Food and Drug Administration for its D3® UltraTM 2009 H1N1 Influenza A Virus ID Kit, a monoclonal antibody fluorescent staining kit for the specific identification of 2009 H1N1 influenza A in direct patient specimens or incubated tissue cultures.

23 Feb 2010

Henry Schein announces net sales increase of 13.0% for fourth-quarter 2009

Henry Schein, Inc., the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended December 26, 2009.

23 Feb 2010

TCAD therapy active and synergistic against drug resistant influenza virus strains

Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.

23 Feb 2010

Research reveals human Chlamydia pneumoniae has originated from animal source

Animals have been found to have infected humans sometime in the past with the common respiratory disease Chlamydia pneumoniae, according to Queensland University of Technology infectious disease expert Professor Peter Timms.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

HHS Secretary reviews H1N1 response at NACCHO conference

Thank you, Tom. I also want to thank NACCHO for hosting this important conference and for inviting me to speak here today. Public health is a top priority for this administration. So is strengthening our partnerships across government. So I’m glad I could come talk with you about how we can work together to keep Americans healthy and safe.

22 Feb 2010

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

Influenza surveillance mechanisms in Mexico were adequate during the fast-spreading H1N1 outbreak in 2009, yet Mexico did not have the infrastructure to quickly identify the emergence of this novel strain, according to an Arizona State University (ASU) epidemiologist.

21 Feb 2010

Quidel acquires Diagnostic Hybrids for $130 million

Quidel Corporation, a leading provider of rapid diagnostic tests, has completed its previously announced acquisition of Diagnostic Hybrids, Inc. for approximately $130 million in cash.

20 Feb 2010

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

BioCrossroads' Indiana Seed Fund has invested in Bioscience Vaccines, Inc. to accelerate the development of biologic materials, which may boost the effectiveness of a wide range of life-saving vaccines.

19 Feb 2010

CMAJ study summarizes risk factors for severe outcome among patients admitted to hospital with H1N1

A new study in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091823 of all patients in Canada admitted to hospital for H1N1 in the first five months of the outbreak summarizes the risk factors for a severe outcome (www.cmaj.ca). The H1N1 pandemic presents important learnings for clinicians and researchers and data on severe outcomes can help inform future treatment and prevention guidelines.

19 Feb 2010

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Novavax, Inc. today presented to the world's leading pandemic influenza vaccine experts a summary of the recent preliminary safety and immunogenicity data from its Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study in Mexico.

19 Feb 2010

Amerigroup's fourth-quarter revenues rise 18.5%

Amerigroup Corporation today announced that net income for the fourth quarter of 2009 was $40.2 million, or $0.79 per diluted share, versus $35.9 million, or $0.67 per diluted share, for the fourth quarter of 2008. For the year ended December 31, 2009, the Company's net income was $149.3 million, or $2.85 per diluted share.

19 Feb 2010

Sacred Heart Medical Center fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards

On January 29, 2010, Sacred Heart Medical Center was cited and fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards. The Department of Labor and Industries Division of Occupational Safety and Health issued the citation and fine for violation of Center for Disease Control and Occupational Safety and Health Administration guidelines on H1N1 and also for violation of the DOSH Directive on Enforcement Procedures for High or Very High Occupational Exposure Risk to the 2009 H1N1 Influenza.

19 Feb 2010

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

BioSante Pharmaceuticals, Inc., will present a LibiGel clinical update at the 2010 Annual Meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH), being held from February 18-20, 2010 in St. Petersburg, Florida.

19 Feb 2010

WHO recommends H1N1 be added to next year's seasonal flu virus

The WHO is recommending the H1N1 (swine flu) virus be added to the regular flu vaccine for the Northern Hemisphere's 2010-2011 regular flu season, the Associated Press reports (2/18).

19 Feb 2010

West Pharmaceutical Services reports 19.9% growth in consolidated fourth-quarter sales

West Pharmaceutical Services, Inc. today announced its results for the fourth quarter and full year of 2009.

18 Feb 2010

In naming Islamic Conference Envoy, Obama highlights global health, food security efforts

During a video address to the 7th U.S.-Islamic World Forum meeting in Doha, Qatar, on Saturday, President Barack Obama appointed Rashad Hussain, deputy associate White House counsel, to serve as Special Envoy to the Organization of the Islamic Conference (OIC), the Associated Press reports.

17 Feb 2010

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

H1N1 News and Research

FDA grants EUA for Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay in CLIA high complexity laboratories

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Henry Schein announces net sales increase of 13.0% for fourth-quarter 2009

TCAD therapy active and synergistic against drug resistant influenza virus strains

Research reveals human Chlamydia pneumoniae has originated from animal source

Study shows CEL-2000 vaccine blocks RA progression in mice

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

HHS Secretary reviews H1N1 response at NACCHO conference

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

Quidel acquires Diagnostic Hybrids for $130 million

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

CMAJ study summarizes risk factors for severe outcome among patients admitted to hospital with H1N1

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Amerigroup's fourth-quarter revenues rise 18.5%

Sacred Heart Medical Center fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

WHO recommends H1N1 be added to next year's seasonal flu virus

West Pharmaceutical Services reports 19.9% growth in consolidated fourth-quarter sales

In naming Islamic Conference Envoy, Obama highlights global health, food security efforts

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News